News - Page 3 of 5 - Immusoft

Investors & Media

Publications & Presentations

MPS I Clinical Update and Outreach Webinar

October 24, 2024

Immusoft
Articles

Immusoft Reports Promising Early Data for Lead Candidate in MPS I

October 17, 2024

Genetic Engineering & Biotechnology News
Articles

First patient who received engineered B cell therapy sees early promise for MPS I

October 15, 2024

Endpoints News
Press Releases

Immusoft to Announce Positive Phase 1 Data for First Engineered B Cell Therapy in a Clinical Trial

September 23, 2024

Immusoft
Articles

B cells as drug factories

June 17, 2024

Nature Biotechnology
Press Releases

Immusoft To Present on ISP-001 Clinical Trial at WORLDSymposium™ 2024 Conference

January 3, 2024

Business Wire
Articles

In a World First, a Patient’s Antibody Cells Were Just Genetically Engineered

December 15, 2023

Wired
Press Releases

Immusoft Administers the First Engineered B Cell in a Human Clinical Trial

December 15, 2023

Immusoft
Press Releases

Immusoft Acquires Exclusive, Worldwide Rights to Intellectual Property for Genome Edited Primary B Cells from the University of Minnesota

March 27, 2023

Immusoft
Press Releases

Immusoft Awarded $8M in Funding from the California Institute for Regenerative Medicine (CIRM) for MPS I Clinical Program

January 27, 2023

Immusoft